We investigated the effect of angiotensin AT! and AT2 receptor blockade on the upper limit of CBF autoregulation in pentobarbital-anesthetized rats. CBF was measured by laser-Doppler flowmetry from the pari etal cortex and MABP was increased by intravenous phenylephrine infusion. Neither the AT! antagonist 10sartan nor the AT2 ligand PD 123319 nor angiotensin II (ANG II) in the presence of losartan affected baseline CBF. When the blood pressure was increased in the con trol group, CBF remained fairly constant up to 145 mm Hg and increased steeply after 150 mm Hg. Both PD 123319 (7-10 mglkg) and losartan (1-10 mglkg) shifted the upper limit of CBF autoregulation toward higher pres-Angiotensin II (ANG II) is a key regulator of car diovascular function. On the basis of displacement with selective ligands, ANG II receptors have been classified in AT) and AT2 subtypes (Chiu et aI., 1989; Whitebread et aI., 1989) . AT) receptors, which mediate ANG II actions such as peripheral vasoconstriction, can be blocked selectively by losartan (DuP 753, DuPort Merck, Wilmington, DE, U.S.A.) (Timmermans et aI., 1991). ANG II binding to AT2 receptors is selectively displaced by PD 123319, but the physiological function of the AT2 receptor has not yet been determined (Bumpus et aI., 1991). There have been several studies in dif ferent species suggesting a possible role for ANG II
sures. Intravenous infusion of PD 123319 was more ef fective than bolus injection. The losartan effect was dose dependent. Selective stimulation of AT 2 receptors with an intravenous ANG II infusion (0.54 J.Lg/min) in the pres ence of losartan did not reverse the effect of losartan on CBF autoregulation, but, on the contrary, appeared to further shift the upper limit of autoregulation toward higher pressures. The results implicate a role for both AT I and AT 2 angiotensin receptors in the regulation of CBF. Key Words: Angiotensin receptors-Cerebrovas cular circulation-Hypertension-Laser-Doppler flow metry-Losartan-PD 123319.
in the control of CBF. ANG II, independently of its hypertensive effects (Phillips, 1987) , protects against the sequelae of brain ischemia in gerbils (Fernandez et aI., 1986) and increases CBF in rab bits (Tamaki et aI., 1992) . Moreover, dog brain mi crovessels contain ANG II receptors (Speth and Harik, 1985) , and recently AT2 receptors were found in cerebral blood vessels of the rat (Tsutsumi and Saavedra, 19910) . Presumably, ANG II con tributes to the modulation of CBF autoregulation in the rat by maintaining the tone of large cerebral resistance vessels (Paulson and Waldemar, 1991) .
Norepinephrine has been reported to directly di late cerebral arteries in rat through activation of J3-adrenergic receptors (Kitazono et aI., 1992) . We found earlier that PD 123319 prevented the norepi nephrine-induced increase in CBF, whereas it did not aff ect baseline CBF (Stromberg et aI., 1992) . In this study, we chose to assess the effects of selec tive AT) and AT 2 receptor ligands on the upper limit of CBF autoregulation, with the use of laser Doppler flowmetry (LDF), while increasing the blood pressure with the pure a-adrenoceptor ago nist phenylephrine. LDP is a reliable and noninva sive method allowing for continuous measurement, and thus detection of rapid changes, of CBP (Tah  moush et aI., 1983; Dirnagl et aI., 1989; Haberl et aI., 1989) . Although LDP measurements are re stricted to assessment of changes in CBP, they have been shown to compare well with more conven tional methods of CBP measurement, such as ra dioactive microspheres, e4C]iodoantipyrine autora diography, H2 clearance, and measurement of pial arteriolar diameter (Tahmoush et aI., 1983; Dirnagl et aI., 1989; Haberl et aI., 1990) .
METHODS
Male Sprague-Dawley rats (Zivic-Miller, Zelienople, PA, U.S.A.) weighing 270-400 g were anesthetized with sodium pentobarbital 60 mg/kg i.p., and additional doses were given as needed to maintain adequate anesthesia. After a tracheotomy the rats were ventilated with room air and supplemental oxygen using a Harvard rodent res pirator (Harvard Apparatus, South Natick, MA, U.S.A.). A small (3 x 3 mm) hole was drilled in the parietal skull bone, leaving the dura mater intact. During drilling, the exposed skull was flushed with saline to prevent thermal injury. An LDP probe (BPM 2 ; Vasamedics, St. Paul, MN, U.S.A.) was fixed in a position close (:;s I mm) to the dural surface. Care was taken to avoid any large arteries in the vicinity of the probe tip. Arterial blood pressure was measured from the aorta with a Spectramed P23XL transducer, which was connected to a catheter inserted in the left femoral artery. The blood pressure and LDP sig nals were recorded simultaneously using a Grass model 79 polygraph (Grass Instrument Co., Quincy, MA, U.S.A.). Arterial blood for blood gas analyses was drawn during the preparative surgery and immediately before and at the end of the experiments from the right femoral artery. The samples were analyzed with a Stat Profile 3 analyzer (Nova Biomedical, Waltham, MA, U.S.A.), and the ventilation was adjusted accordingly to keep P aco2 between 35 and 40 mm Hg. Rectal temperature was main tained at 36.5-37SC by using a heating pad. To increase the blood pressure, phenylephrine was in fused intravenously (femoral vein) in increasing amounts (0.1-10 fLg/min) to reach a sudden increase in CBP, indi cating the loss of autoregulation. The recorded CBP val ues were plotted as relative to baseline (100%) against MABP to generate autoregulation curves.
The drugs used were the AT2-selective PD 123319 {I [[4-( dimethylamino)-3-methylpheny l]methy 1]-5 -( diphe nylacetyl)-4,5 ,6,7 -tetrahydro-lH-imidazo[ 4,5-c ]pyridine-6-carboxylic acid; Parke-Davis, Ann Arbor, MI, U.S.A.}, the ATe selective losartan potassium (DuPont Merck), human ANG II (Peninsula, Belmont, CA, U.S.A.), and phenylephrine hydrochloride (Sigma, St. Louis, MO, U.S.A.). The experimental groups were (a) saline, (b) PD 123319 at 10 mg/kg, (c) PD 123319 at 0.36 mg/kg/min, (d) losartan at 1 and 10 mg/kg, and (e) ANG II + losartan. In groups a, b, and d, the drugs were given as intravenous injections via the femoral vein, 5 min before starting the phenylephrine infusion, in vols of 1 mUkg. A single dose of losartan has been shown effectively to block AT 1 re-ceptors for at least 90 min (Wong et a!., 1990) , and prob ably longer, since its elimination half-life in rats is 5.7 h (Smith et a!., 1992) . Por PD 123319 such information is not available. Therefore, in group c PD 123319 was in fused intravenously throughout the experiment at a rate of 2.1 fLUmin, and the phenylephrine infusion was started after a 5-min infusion with PD 123319. In group e ANG II was infused intravenously throughout the experiment at 0.5 fLg/min. The pressor response to ANG II was con firmed in each rat by letting the MABP rise to -140 mm Hg. When this pressure was reached, losartan was given in repeated 2-mg/kg doses until the MABP returned to baseline. Thereafter phenylephrine was infused as in the other groups.
The cerebrovascular responsiveness was assessed in all animals after the drug treatments by ventilating the rats with 5% CO2 in air. Based on preliminary experiments, a 50% increase in CBP was easily elicited in control ani mals. Therefore, if a similar increase was obtained after the given treatments, normal cerebrovascular responsive ness was assumed. This criterion was fulfilled in all tested animals.
After the experiment, the animals were killed with an intravenous bolus of concentrated KCI. The experiments were carried out in accordance with the National Insti tutes of Health guidelines for experimental animal re search.
The statistical treatment of the CBP/MABP curves in cluded a two-way repeated measures analysis of variance in which the 6 treatments were the between-subjects fac tor and 18 consecutive MABP values (124-157 mm Hg) were the within-subjects factor. Blood gas values were compared with one-way analysis of variance and Tukey's test. Baseline values and 5-min postdrug values for MABP and CBP were compared by paired t test.
RESULTS
The arterial blood gas values in the different treatment groups immediately before the experi ment are shown in Table 1 . There were no differ ences between groups.
In all experiments, the effects of the given treat ments on MABP and CBP were assessed before starting the phenylephrine infusion (Table 2) . Lo sartan, 1 and 10 mg/kg, lowered MABP slightly and Values are means ± SO for five rats. There are no statistically significant differences between groups (Tukey's test). dose dependently. Other treatments did not affect the baseline MABP, although a 2-mm Hg increase in the PD 123319 infusion group reached statistical significance. None of these treatments affected baseline CBF. The analysis of the CBF/MABP curves showed that the drug * MABP interaction was statistically significant: F(18,357) = 3.8, p < 0.001 (Green house-Geisser E corrected value). This meant that the curves were different (i.e., not parallel). We then explored whether the five active treatment groups (groups b-e) differed from each other in terms of drug * MABP interaction. The nonsignifi cant interaction term in this comparison indicated that the autoregulation curves for the five treat ments were similar. Therefore, we pooled the data from groups b-e and compared them with the saline group again using the repeated measures analysis of variance. This comparison gave a statistically sig nificant drug * MABP interaction [F(18,425) = 17.3, p < 0.001], indicating that all treatment groups b-e were different from the saline group. In the saline group (group a), autoregulation was maintained effectively up to an MABP of 145 mm Hg, after which there was a variable increase in CBF between 145 and 150 mm Hg. When MABP exceeded 150 mm Hg, the autoregulation was com pletely lost in all animals due to forceful dilation of the resistance vessels ( Figs. 1-3) .
The AT 2 receptor ligand PD 123319 increased the autoregulatory range at both to-mg/kg (group b) and 0.36-mg/kg/min (group c) infusions. The loss of au toregulation was seen only at pressures above 155 mm Hg (Fig. 1) . The mean cumulative dose in the infusion group was 7.0 mg/kg (range 6.7-7.2 mg/kg).
Blockade of AT 1 receptors by losartan (group d) also increased the autoregulatory range. The loss of autoregulation was seen, as with PD 123319, after � 155 mm Hg (Fig. 2) . Although the two doses were not statistically different, autoregulation was lost in some of the lower-dose (1 mg/kg) animals slightly earlier.
To assess a possible effect of AT2 receptor stim ulation, ANG II was infused in the presence of a dose of losartan that was able to block the pressor effect of ANG II (group e). Under these conditions, it was assumed that there was no significant AT) receptor stimulation. The mean dose of losartan re quired to keep MABP at baseline level was 6.8 mg/ kg (range 4-10 mg/kg). Infusion of ANG II, in ad dition to phenylephrine, did not counteract the ef fect of losartan on the autoregulation. On the contrary, it shifted the upper limit of autoregulation to even higher pressures than losartan alone (Figs. 2 and 3). With this combination, autoregulation was lost only at pressures exceeding 165 mm Hg. At the end of the experiment, it was confirmed that there still was effective AT) blockade by losartan. When the phenylephrine infusion was discontinued, while 
DISCUSSION
CBF is not directly proportional to systemic blood pressure, but is kept fairly constant over a wide range of pressures due to autoregulatory ad aptation. CBF autoregulation is subject to several modulatory factors, and detection of changes in this system requires alteration of blood pressure (Paul son et al., 1990) . Contraction of large cerebral ar teries is mainly responsible for the autoregulation at the highest blood pressures, whereas the smaller vessels are already undergoing dilation at this stage . Therefore, the upper range of autoregulation reflects mainly contraction of the large resistance vessels. In our experiment, the upper limit of autoregula tion in the control group corresponds to earlier find ings in anesthetized normotensive rats (Hernandez et al., 1978; Siesj6 et al., 1983) . As in those exper iments different anesthetic agents were used, it is not likely that pentobarbital had a significant effect on the autoregulation curves. On the other hand, pentobarbital does not interfere with ANG 11induced vasoconstriction (McShane et al., 1989) .
The inability of ANG II to modify the CBF, when blood pressure is maintained at resting levels, has led in previous studies to the conclusion that ANG II does not have a direct action on cerebral vessels (Greenfield and Tindall, 1968; Olesen, 1972) . On the other hand, a role for ANG II in CBF autoregula tion has been implicated by studies in which ANG II production was inhibited by angiotensin convert ing enzyme inhibitors. Captopril shifted the upper ANG II + losartan shifts the upper limit of auto regulation toward higher pressures. limit of autoregulation toward lower pressures (Barry et aI., 1984; Waldemar et aI., 1989; Postigli one et aI., 1991) . ANG II may have a protective effect against stroke by constricting the large cere bral arteries during hypertension (Brown and Brown, 1986 ). However, a constrictive effect of ANG II on large cerebral arteries has not been proven, whereas ANG II has been shown to con strict (Wei et aI., 1978; Joyner et aI., 1988) or dilate (Haberl et aI., 1990) smaller cerebral vessels.
The present experiments were inspired by the earlier finding that large cerebral arteries contain exclusively the AT2 subtype of ANG II receptors (Tsutsumi and Saavedra, 1991a) . Recently we re ported that the AT2-selective ligand PD 123319 pre vents the norepinephrine-induced increase in CBF (Stromberg et aI., 1992) . As the effect of specific ANG II receptor ligands on CBF autoregulation has not been studied, we designed this experiment to assess whether PD 123319 would have an effect on the upper limit of CBF autoregulation. Even though cerebral arteries have not been found to express AT! receptors, the effect of the AT\ antagonist 10sartan was assessed comparatively. As it is not known whether PD 123319 acts as an AT2 receptor agonist or antagonist, we included a group in which ANG II was infused in the presence of losartan to stimulate AT 2 receptors selectively.
We demonstrate that both PD 123319 and losar tan alone were able to shift the upper limit of CBF autoregulation toward higher pressures. The stimu lation of AT2 receptors by ANG II in the presence of losartan further shifted the limit of autoregula tion, and this combination was the most effective in our study. In the PD 123319 and losartan groups, the autoregulation was completely lost at an MABP �5 mm Hg higher than in the control animals. In the ANG II + losartan group, this limit was shifted by 15 mm Hg.
We observed a similar effect with both the AT\ selective losartan and the AT2-selective PD 123319. Both compounds have also recently been shown to antagonize the ANG II-induced dilation of pial ar teries (Brix and Haberl, 1992) . This could suggest that the drugs act on the same receptor subtype or that both subtypes are involved. As both drugs are highly selective for their respective receptor sub types (Dudley et aI., 1990; Timmermans et aI., 1991) , it is reasonable to believe that, at the doses given here, they did not cross-react with the other subtype.
We offer two possible explanations for the pre sent results. The first hypothesis assumes a dual effect of ANG II on cerebral vessels. Constriction of cerebral vessels by stimulation of AT 2 receptors J Cereb Blood Flow Metab, Vol. 13, No.2, 1993 and dilation through AT \ receptor stimulation can explain why losartan, by AT \ blockade, shifts the upper limit of autoregulation to higher pressures. Accordingly, combined AT2 stimulation and AT\ blockade, after infusion of ANG II in the presence of losartan, extends autoregulation to still higher pressures. Given the AT2 selectivity of PD 123319, this interpretation suggests an agonist effect of this compound on arterial AT 2 receptors.
Alternatively, AT \ receptors do not need to play a role in the CBF response, as administration of losartan increases plasma ANG II levels severalfold (Mizuno et aI., 1992) and consequently could indi rectly elicit AT2 receptor stimulation. Also, by this theory PD 123319 would be an AT2 receptor ago nist. Consistent with this explanation is the obser vation of a shift in the autoregulation toward lower pressures after inhibition of ANG II formation with captopril (Barry et aI., 1984; Waldemar et aI., 1989; Postiglione et aI., 1991) . We cannot, of course, rule out the possibility that the compounds act on an as yet unidentified ANG II receptor.
Finally, it should be added that ANG II acts on structures that indirectly influence CBF (Speth et aI., 1987; Andreatta et aI., 1988; Gehlert et aI., 1990; Maeda et aI., 1991; Stromberg et aI., 1991; Tsutsumi and Saavedra, 1991b; Hawcock et aI., 1992) . How ever, it is questionable whether losartan in the doses used penetrates the blood-brain barrier (Bui and Phillips, 1992) .
Taken together, our results, and those of other groups, indicate a significant role for the renin angiotensin system, and especially the AT 2 recep tors, in the regulation of cerebrovascular tone. Nonpeptide drugs with selectivity for AT, or AT2 receptors may prove useful for the treatment or pre vention of stroke or other cerebrovascular disor ders.
